摘要
表皮生长因子受体(EGFR)信号通路在胰腺癌的增殖、转移、血管形成等方面有重要作用,人们对胰腺癌的EGFR信号通路进行了深入全面的研究,并对EGFR抑制剂和K-ras抑制剂治疗胰腺癌进行了大量临床试验。虽然厄洛替尼被美国食品药物管理局批准用于治疗晚期胰腺癌,但其仅延长中位生存期不到10 d,且皮疹、腹泻等不良反应影响了患者生活质量,是否真正使患者临床受益仍存在争议。
Epidermal growth factor receptor（EGFR）signaling pathway has an important role in proliferation,migration,angiogenesis of pancreatic cancer,which leads to the deep and comprehensive study of this pathway.A lot of clinical trials for EGFR inhibitors and K-ras inhibitors have been done.Erlotinib has been approved by FDA US for the treatment of the advanced pancreatic cancer,but it only prolongs the median survival of patients less than ten days,and its side effects of rash and diarrhea affect the quality of life of the patients,so its clinical benefit is still controversial.
出处
《医学综述》
2012年第21期3573-3576,共4页
Medical Recapitulate
关键词
表皮生长因子
胰腺癌
K-RAS
Epidermal growth factor
Pancreatic neoplasms
K-ras
